Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.
The in vitro activities of four new beta-lactam antimicrobial agents (moxalactam, cefotaxime, cefoperazone, and piperacillin) and the aminoglycosides against 744 recent clinical isolates of facultative gram-negative bacilli were compared simultaneously by the agar dilution method. The major in vitro difference of these newer beta-lactam compounds appeared to be their antipseudomonal activity; cefoperazone was the most active, whereas cefotaxime had the least potency. The aminoglycosides, however, had the most effective in vitro activity on a weight basis against Pseudomonas aeruginosa.
D000617:Aminoglycosides / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D002438:Cefoperazone; D002439:Cefotaxime; D002511:Cephalosporins / Q000494:pharmacology*; D002513:Cephamycins / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D009070:Moxalactam; D010406:Penicillins / Q000494:pharmacology*; D010878:Piperacillin; D011550:Pseudomonas aeruginosa / Q000187:drug effects
D000617:Aminoglycosides; D002511:Cephalosporins; D002513:Cephamycins; D010406:Penicillins; D002438:Cefoperazone; D002439:Cefotaxime; D009070:Moxalactam; D010878:Piperacillin